Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • NEWS AND VIEWS

Insights into the origins of pancreatic cancer

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Nature 597, 641-642 (2021)

doi: https://doi.org/10.1038/d41586-021-02435-4

References

  1. 1.

    Grimont, A., Leach, S. D. & Chadwani, R. Cell. Mol. Gastroenterol. Hepatol. https://doi.org/10.1016/j.jcmgh.2021.07.014 (2021).

    Article  Google Scholar 

  2. 2.

    Neuhöfer, P. et al. Nature 597, 715–719 (2021).

    Article  Google Scholar 

  3. 3.

    Fischer, C. G. & Wood, L. D. J. Pathol. 246, 395–404 (2018).

    PubMed  Article  Google Scholar 

  4. 4.

    Kipling, D. & Cooke, H. J. Nature 347, 400–402 (1990).

    PubMed  Article  Google Scholar 

  5. 5.

    van Heek, N. T. et al. Am. J. Pathol. 161, 1541–1547 (2002).

    PubMed  Article  Google Scholar 

Download references

Competing Interests

A.M. receives royalties for a pancreatic cancer biomarker test from Cosmos Wisdom Biotechnology, and this financial relationship is managed and monitored by the UTMDACC Conflict of Interest Committee. A.M. also receives royalties as an inventor on a patent that has been licensed by Johns Hopkins University to Thrive Earlier Detection (an Exact Sciences Company). A.M. serves as a consultant for Freenome.

Subjects

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Quick links